Making operating systems safer and faster with ‘unikernels’
28 Jan 2016Technology to improve the security, speed and scale of data processing in age of the Internet of Things is being developed by a Cambridge spin-out company.
Innovation is about the application of new ideas, discoveries and inventions. The innovative and entrepreneurial spirit of the members of the University of Cambridge is enshrined in the University’s mission statement to contribute to society through the pursuit of education, learning and research at the highest international levels of excellence. The foundation for innovation is the steady supply of excellent ideas, of which there is an abundance at Cambridge. Ingenuity and creativity, alongside the fundamental research which underpins these ideas and combined with the constant exchange of ideas between academics and companies, governments and NGOs has been the recipe for this success.
Various mechanisms are in place to help our academics nurture future innovation. As well as dedicated departmental support structures, Cambridge Enterprise provides technology transfer, consultancy services and seed fund opportunities, and the Centre for Entrepreneurial Learning (CfEL) within the Judge Business School provides networking opportunities with peers. In addition, Cambridge-based initiatives physically embedded within the University such as ideaSpace provide hubs for entrepreneurs to develop ideas.
Technology to improve the security, speed and scale of data processing in age of the Internet of Things is being developed by a Cambridge spin-out company.
For the third consecutive year, the University of Cambridge has broken its early stage investment record, approving 13 seed fund investments for a total of £3.8 million, an increase on the £3.2 million invested in 2013-14.
Three global pharmaceutical companies and the technology transfer offices of three world-leading universities – Imperial College London, University College London and the University of Cambridge – have joined forces with a combined £40 million to create the Apollo Therapeutics Fund.
A new thin-film electrolyte material that helps solid oxide fuel cells operate more efficiently and cheaply than those composed of conventional materials, and has potential applications for portable power sources, has been developed at the University of Cambridge.
A collaboration between the University of Cambridge and MedImmune, the global biologics research and development arm of AstraZeneca, has led researchers to identify a potentially significant new application for a well-known human enzyme, which may have implications for treating respiratory diseases such as asthma.